FDA grants tentative approval for Teva's Cinacalcet HCl Tablets ANDA

May 15 2010NewsGuard 100/100 Score

Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) announced today that the U.S. Food and Drug Administration (FDA) has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) for Cinacalcet HCl Tablets 30, 60 & 90 mg.

Upon final approval, Teva's Cinacalcet HCl Tablets will be the AB-rated generic equivalent of Amgen's Sensipar®, indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis.

The brand product had annual sales of approximately $458 million in the United States, based on IMS sales data.

Teva is currently involved in patent litigation concerning this product in the U.S. District Court for the District of Delaware. A trial date has not been set.

SOURCE Teva Pharmaceutical Industries Ltd.,

Posted in: Medical Condition News | Pharmaceutical News

Tags: , , , , , , , , , , , , , ,

Comments (0)

Suggested Reading

Social media normalizes unhealthy food choices, shaping youth habits and brand loyalty
Not all ultra-processed foods are made alike: Researchers warn against villainizing entire food group
Limiting fast-food outlets can reduce childhood overweight and obesity
Ultra-processed food linked to weight gain and lower well-being in adolescents
High levels of microplastics found in prostate tumors, possibly linked to take-out food
Updated Food Compass 2.0 improves food health ratings using new diet data
Online food shopping: Are you getting the information you need?
Six common flying with food allergies myths

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Ultra-processed foods dominate children's diets from toddlerhood to middle childhood